Navigation Links
Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
Date:12/4/2008

DURHAM, N.C., Dec. 4 /PRNewswire/ -- Parion Sciences, Inc. today announced that its partner, Gilead Sciences (Nasdaq: GILD), has initiated a Phase I clinical trial of GS9411 in healthy volunteers to evaluate the safety and tolerability of the investigational compound. GS9411 is designed to increase airway hydration for the treatment of pulmonary disease. Previously known as P-680, GS9411 is an epithelial sodium channel (ENaC) blocker discovered by Parion, a privately held pharmaceutical company focused on treating diseases that result from the failure of the body's mucosal defenses.

The initiation of the Phase I trial triggers a $5 million milestone payment to Parion, according to an exclusive licensing and co-development agreement signed in August 2007 granting Gilead worldwide commercialization rights to GS9411 for the treatment of pulmonary diseases, including cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) and non-CF bronchiectasis. Parion and Gilead jointly performed the IND-enabling studies for GS9411, and Gilead will assume primary development responsibilities going forward. The two companies are also collaborating on a research program to identify other promising ENaC blocker-based drug candidates utilizing Parion's proprietary ENaC-based chemistry platform.

"This is an important milestone in our program to develop ENaC inhibitors to treat a range of diseases through restoring and maintaining the hydration of mucosal surfaces," said Paul Boucher, Sr. Director, Finance and Business at Parion. "Our partnership with Gilead has enabled us to accelerate development of GS9411 and successfully meet the goals and timelines for this project. We look forward to discovering the potential of this compound to provide a new treatment option for patients suffering from cystic fibrosis, COPD and other serious lung conditions."

Epithelial sodium channel blockers, such as GS9411, are unique therapeutic agents developed to maintain and stimulate hydration on the body's mucosal surfaces, including those on the lung, mouth, nose, eye and gastrointestinal tract. Restoring the hydration of mucosal airway surfaces addresses the fundamental problem that predisposes individuals to infections in both acquired and genetic forms of chronic lung disease, including COPD and CF.

About Parion Sciences

Based in Durham, NC, Parion Sciences is a privately-held, development-stage pharmaceutical company that is leveraging its proprietary small molecule chemistry and epithelial biology expertise to discover and develop an innovative pipeline of therapies for diseases resulting from the failure of the body's mucosal defenses, including chronic obstructive pulmonary disorder (COPD), cystic fibrosis, bronchiactesis and Sjogren's syndrome. Parion's lead product candidate, P-552, is currently in Phase II clinical development for the treatment dry mouth associated with Sjogren's syndrome. Parion was founded based on technology from University of North Carolina, Chapel Hill (UNC-CH) and has received grant funding from the National Institutes of Health (NIH) and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT) For more information, please visit www.parion.com.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

For information about the Cystic Fibrosis Foundation, please visit www.cff.org .


'/>"/>
SOURCE Parion Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Parion Sciences and Kainos Medicines Sign Clinical Development Agreement for Novel Dry Mouth Treatment
2. CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East
3. Advanced Life Sciences Announces Cethromycin NDA Accepted for Filing by FDA for the Treatment of Community Acquired Pneumonia
4. DuPont Applied BioSciences Selects MBI to Collaborate on Process Development and Scale-Up for New Bio-based Product
5. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
6. Frost & Sullivan Recognizes Martek Biosciences for Unique and Customer-Focused Strategies With Customer Value Enhancement Award
7. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
8. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
9. Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
10. Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO
11. Neurocrine Biosciences to Present at the 20th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Rockville, Maryland (PRWEB) , ... May 24, 2016 ... ... introduction of a newly re-branded identity. The new Media Cybernetics corporate branding reflects ... the world of imaging and image analysis. The re-branding components include a crisp, ...
(Date:5/23/2016)... , May 23, 2016 Zimmer Biomet Holdings, Inc. ... today announced that its Board of Directors has approved the ... second quarter of 2016. The cash dividend ... July 29, 2016 to stockholders of record as of the ... dividends are subject to approval of the Board of Directors ...
(Date:5/23/2016)... ... May 23, 2016 , ... RoviSys, a leading ... in Aurora, Ohio, has broken ground on a new building in Holly Springs, ... area, this new location solidifies a commitment to business in the region. The ...
(Date:5/20/2016)... (PRWEB) , ... May 20, 2016 , ... The leading ... of its most experienced veterinary clients have treated over 100 of their own patients ... technology to provide the highest level of care for their patients. , The ...
Breaking Biology Technology:
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
Breaking Biology News(10 mins):